Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologist who treat patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Brian Abbott, MD, Medical Director of Hematology
Brian Abbott, MD, Medical Director of Hematology
Big Sky Oncology
May 19, 2008
TREANDA for CLL could be a winner
Analysis of: FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma (www.pipelinereview.com)
The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.
Brian Abbott, MD, Medical Director of Hematology
Brian Abbott, MD, Medical Director of Hematology
Big Sky Oncology
May 19, 2008
National healthcare? Better find a new pool of physicians
Analysis of: Look to England's example for ways to solve America's health-care problem (www.sltrib.com)
National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?
Brian Abbott, MD, Medical Director of Hematology
Brian Abbott, MD, Medical Director of Hematology
Big Sky Oncology
May 19, 2008
Medicare: heading toward a crisis
Analysis of: Loss of Doctors Leaves Patients Waiting (www.redorbit.com)
The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.
May 19, 2008
The gods giveth and then takith away- Go figure.....
By a GLG Expert Contributor
Analysis of: First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations (jco.ascopubs.org)
Two papers, the one above, and http://jco.ascopubs.org/cgi/content/full/26/15/2450 reveal somewhat conflicting data on AstraZeneca's Iressa that was until now on the "back burner" due to Genentech's Tarceva, that had better response data than Iressa in separate trials On one hand the first paper points...
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
May 19, 2008
BRCA Mutations less risky than thought
Analysis of: Cancer-Gene Test Boosts Myriad's Sales (online.wsj.com)
New data indicates risk of invasive breast cancer in women with either BRCA mutation maybe less than previuosly thought This new information will adversely impact Myriad's business
May 19, 2008
Alimta (Lilly): YES!!!!
By a GLG Expert Contributor
Analysis of: Lilly Drug Shown to Slow Lung Cancer (online.wsj.com)
That Alimta can be effectively used after other chemotherapy in non small cell lung cancer (NSCLC) as a maintenance agent!
May 15, 2008
Novo Nordisk: Good try but recombinant activated factor VII did not reach its goal in hemorrhagic stoke
By a GLG Expert Contributor
Analysis of: Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage (content.nejm.org)
"In summary, rFVIIa reduced hematoma growth but did not reduce the rate of death or severe disability after intracerebral hemorrhage."
May 13, 2008
GSK: Gutsy but logical clinical trial of Tykerb v Herceptin (Genentech)
By a GLG Expert Contributor
Analysis of: Glaxo Tests Tykerb vs Herceptin in Early Cancer (www.therapeuticsdaily.com)
Glaxo is trying to move Tykerb ahead of Herceptin in a first line/neoajuvant/adjuvant setting in Her2Neu + Breast cancer.
May 12, 2008
ImClone: Does Morgan Stanley (MS) know something we don't??
By a GLG Expert Contributor
Analysis of: US Drug Stocks Edge Higher, But ImClone Falls On Downgrade (news.ino.com)
Erbitux was touted to have a positive study in Non Small Cell Lung Cancer (NSCLCA) but all they said was that is was a positive study. No further info at that time but an executive bought a block of stock a few days before the announcement which led to an inevitable rise in the stock price! Does this...
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
May 9, 2008
ASA404 approach in treating lung cancer
Analysis of: ASA404 begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death (www.pipelinereview.com)
ASA404 begins pivotal trial to explore new approach in treating lung cancer ASA404 is a drug that helps chemo treat lung cancer yet eliminate exisiting blood vessels supplying the tumors

Previous Page : 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Next131 to 140 of 773

Analytics


Generated at 2009-01-07T13:00:17.563